Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Q: Why study immune responses in lungs?

Ling-Pei Ho: Most people understand the immune system as a collection of tissues and cells that help the body defend itself against infection - but is does more than that. The immune system has to be able to tolerate non-dangerous microbes, particularly in an organ like the lung where it is exposed to the environment every minute of the day. It needs to recognise what is and what is not harmful. It also needs to be able to regulate itself.  If any of these functions fail, then disease can ensue; one of these is sarcoidosis.  

Sarcoidosis is an immune disorder which can affect any organ in the body but primarily affects the lungs. For most patients the collection of symptoms is relatively mild, such as a cough, but for about 40% of patients it can be quite severe. Patients can become breathless due to excessive immune response (in the form of granuloma formation) or scarring (fibrosis). The condition can last for many years and in the worst affected patients this can lead to respiratory failure.

Q: What causes sarcoidosis?

LPH: The exact cause of sarcoidosis is unknown but we do know it is the result of an exaggerated immune response to an unknown environmental trigger. In Oxford we are more interested in defining the problems in the immune response rather than the triggers. For example, we have found that a group of powerful immune cells called the natural killer T cells are absent in a lot of patients with sarcoidosis. This group of immune cells controls the immune system, and loss of these cells could be a cause for excessive immune activity.

Q: What are the most important lines of research that have developed in the last 5-10 years?

LPH: The discovery from genome wide association studies that genes involved in regulating the immune system supports the idea that inability to regulate the immune response is one of the key mechanisms of this disease.

Q: Why does your line of research matter and why should we put money in to it?

LPH: Understanding the exact pathways causing the disease, or the cells that are involved, helps us find out which molecules or cells we can target for new therapies for this condition, particularly for those with lung scarring (fibrotic sarcoidosis). There are few new medicines available for sarcoidosis, and in fact the last 50 years we have not had a single medicine made specifically for sarcoidosis.

Q: How does your research fit into translational medicine within the Department?

LPH: We have shown that loss of natural killer T cells in sarcoidosis results in abnormal monocyte and T cell responses. We are now examining the causes of fibrotic sarcoidosis. These studies will provide a basis for new, or repositioning of current, drugs to the more severe end of the disease.

Ling-Pei Ho

Professor Ling-Pei Ho tries to understand how immune responses in the lung impact on the mechanisms on the natural mechanisms of injury and repair. She works with patients with diseases such as idiopathic pulmonary fibrosis (IPF), where the medial survival is only three years, with lung function slowly being lost. By combining research in the lab and with patients, Professor Ho's work is yielding clues for a cure to these diseases.

More podcasts related to Translational & Clinical

David Stuart: Structural biology and vaccines

The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.

Kay Grunewald: Structural cell biology of virus infection

Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.

Jens Rittscher: Biological imaging

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Fluorescence labelling helps make intrinsic cellular functions visible and computational tools then enable analysis of these data sets to improve our understanding of cellular functions.

Sebastian Nijman: Pharmacogenomics

In the context of cancer, genetic diversity means that we respond differently to various treatments. Pharmacogenomics sits at the intersection between genetics and drugs. Better understanding of the genetic landscape of cancer and the recent increase of targeted drugs allow us to better match patients with the best treatments, improving care.

Ian Pavord: Asthma

Ian Pavord's research in to airway inflammation has resulted in mepolizumab being identified as an effective inhibitor of eosinophilic inflammation and asthma attacks. Mepolizumab is currently in Phase III clinical trials and if found to be effective could be a promising treatment for certain asthma patients.

Trudie Lang: The Global Health Network

The Global Health Network is a successful and growing online science park comprised of varied research communities for different health research groups and cross-cutting health topics. It is built for the research and wider health community by researchers and public health practitioners themselves. It is a trusted source of quality information, education and research tools.

Najib Rahman: Respiratory Medicine

Respiratory medicine encompasses a large number of common diseases like pneumonia, asthma, emphysema and lung cancer. Outcomes are currently relatively poor and the area of research is underfunded. Recent progress have been made towards personalising treatment, and Dr Rahman's research aims at improving patient care.

Chris O’Callaghan: Atherosclerosis & immunity

Atherosclerosis is the most important cause of death worldwide. It is caused by the accumulation of both fatty material and immune cells. Over time, these set up an inflammatory reaction which causes a lot of damage to the blood vessel wall. Although we do have good therapies designed to lower the levels of fatty material, we haven’t any therapies specifically designed to target the effect of the immune system. Professor O'Callaghan's group is working towards developing such therapies.

Stefan Knapp: Development of chemical probes

While drugs were initially developped by testing natural products directly in humans, the current approach is to use chemical probes. These are small chemical coumpounds that inhibit selected targets, avoiding side effects. Professor Knapp produces structures of molecular targets and makes them widely available. This will allow a faster and more cost effective development of new drugs.

Chas Bountra: Drug Discovery

Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition from basic research to clinical trials, producing new therapies for patients.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.